Physician profile
Sherry Bragg
NPI 1942673843
$2,972.80
in general payments reported to CMS, 2019-2025
27 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $580 · 2023: $528 · 2024: $752 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $516.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $359.23 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $259.68 | 2021-2025 | Airsupra, Farxiga, Nexium |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.09 | 2021-2024 | Xifaxan |
| Abbvie INC. | $213.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.00 | 2021-2022 | |
| Lilly USA, LLC | $206.55 | 2021-2024 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $148.04 | 2021-2025 | Freestyle Libre 2 |
| Amgen INC. | $141.58 | 2021-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $97.79 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.58 | 2021-2023 | Eliquis |
| Mylan Specialty L.P. | $56.68 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $48.56 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $41.91 | 2021 | |
| Almatica Pharma LLC | $39.35 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $38.61 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.34 | 2024 | |
| Nestle Healthcare Nutrition INC. | $37.01 | 2023 | |
| Pfizer INC. | $37.00 | 2024-2025 | |
| Dexcom, INC. | $30.95 | 2021-2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $30.55 | 2021 | |
| Merck Sharp & Dohme LLC | $28.67 | 2022-2023 | Verquvo, Belsomra |
| Xeris Pharmaceuticals, INC. | $22.64 | 2024 | Gvoke Hypopen |
| Verona Pharma, INC. | $17.92 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $17.36 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $14.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Bragg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.